mRNA expression of dopamine receptor D2 and dopamine transporter in peripheral blood lymphocytes before and after treatment in children with tic disorder
JI Xiao-Yi1, WU Min2
Department of Pediatrics, Jiaxing Maternity and Child Health Care Hospital, Jiaxing, Zhejiang 314000, China
Abstract Objective To investigate the mRNA expression of dopamine receptor D2 (DRD2) and dopamine transporter (DAT) in peripheral blood lymphocytes before and after treatment in children with tic disorder (TD). Methods RT-PCR was used to measure the mRNA expression of DRD2 and DAT in peripheral blood lymphocytes before and after treatment in 60 children with TD. The correlations between mRNA expression of DRD2 and DAT and the severity of TD were analyzed. Sixty healthy children served as the control group. Results Before treatment, the children with TD had a significant increase in the mRNA expression of DRD2 and DAT compared with the control group (PPPPConclusions In children with TD, the mRNA expression of DRD2 in peripheral blood lymphocytes can be used as one of the indicators for diagnosing TD, assessing the severity of TD, and evaluating clinical outcomes.
JI Xiao-Yi,WU Min. mRNA expression of dopamine receptor D2 and dopamine transporter in peripheral blood lymphocytes before and after treatment in children with tic disorder[J]. CJCP, 2016, 18(4): 297-300.
JI Xiao-Yi,WU Min. mRNA expression of dopamine receptor D2 and dopamine transporter in peripheral blood lymphocytes before and after treatment in children with tic disorder[J]. CJCP, 2016, 18(4): 297-300.
Cath DC, Hedderly T, Ludolph AG, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment[J]. Eur Child Adolesc Psychiatry, 2011, 20(4): 155-171.
Herzberg I, Valencia-Duarte AV, Kay VA, et al. Association of DRD2 variants and Gilles de la Tourette syndrome in a familybased sample from a South American population isolate[J]. Psychiatr Genet, 2010, 20(4): 179-183.
[4]
Taylor JL, Rajbhandari AK, Berridge KC, et al. Dopamine receptor mo-dulation of repetitive grooming actions in the rat. Potential relevance for Tourette syndrome[J]. Brain Res, 2010, 31(1322): 92-101.
[5]
Nikolaus S, Antke C, Muller HW. In vivo imaging of synaptic funtion in the central nervous system: II. Mental and afective disorders[J]. Behav Brain Res, 2009, 204(1): 32-66.
[6]
Steeves TDL, Ji HK, Kideckel DM, et al. Extrastriatal dopaminergic dys-function in Tourette syndrome[J]. Ann Neurol, 2010, 67(2): 170-181.
[7]
Liu H, Dang F, Meng Z, et al. Evaluation of Tourette's syndrome by (99m) Tc-TRODAT-ISPECT/CT imaging[J]. Ann Nucl Med, 2010, 24(7): 515-521.
[8]
Li JJ, Li ZW, Li AY, et al. Abnormal expression of dopamine and sero-tonin transporters associated with the pathophysiologic mechanism of Tourette syndrome[J]. Neurol India, 2010, 58(4): 523-529.
[9]
Osladali MR, Ahangari G, Eslami MB, et al. The detection of dopamine gene receptors(DRD1-DRD5)expression on human peripheral blood lymphocytes by real time PCR[J]. Iran J Allergy Asthma Immunol, 2004, 3(4): 169-174.
[10]
Rocc P, De Leo C, Eva C, et al. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2002, 26(6): 1155-1160.
[11]
Rollins B, Martin MV, Morgan L, et al. Analysis of whole genomebiomarker expression in blood and brain[J]. Am J Med Genet B Neuropsychiatr Genet, 2010, 153B(4): 919-936.
VE Caballo. Diagnostic and statistical manual of mental disorders[M]. 4th ed. Washington, D.C. American Psychiatric Association, 1994: 1-50.
[16]
Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity[J]. J Am Acad Child Adolesc Psychiatry, 1989, 28(4): 566-573.
Davies L, Stern JS, Agrawal N. A case series of patients with Tourette syndrome in the United Kingdom treated with aripiprazole[J]. Hum Psychopharmacol, 2006, 21(7): 447-453.
[19]
Miranda CM, Castiglioni TC. Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients[J]. Rev Med Chil, 2007, 135(6): 773-776.
[20]
Yoon DY, Gause CD, Leckman JF, et al. Frontal dopaminergic abnormality in Tourette syndrome: A postmortem analysis[J]. J Neurol Sci, 2007, 255(1-2): 50-56.
[21]
Minzer K, Lee O, Hong JJ, et al. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum[J]. J Neurol Sci, 2004, 219(1-2): 55-61.
